ENDRA Life Sciences, Inc.

As of October 1, 2023, ENDRA Life Sciences, Inc. is considered attractive and undervalued with a P/E ratio of 15.2 and a P/B ratio of 1.8, especially when compared to peers like NanoString Technologies and Veracyte, and its recent performance has outpaced the Sensex.

As of May 9, 2025, the market trend is mildly bearish with weak overall strength, indicated by bearish daily moving averages and Bollinger Bands, despite some mildly bullish signals from the MACD.

As of March 2022, the management team of ENDRA Life Sciences, Inc. is led by Mr. Francois Michelon as Chairman and CEO, with independent directors including Mr. Louis Basenese, Mr. Anthony DiGiandomenico, Dr. Sanjiv Gambhir, Mr. Michael Harsh, and Mr. Alexander Tokman.

ENDRA Life Sciences, Inc. commercializes enhanced ultrasound technology for pre-clinical research in the Pharmaceuticals & Biotechnology sector. It has a market cap of $2.45 million and reported a net profit loss of $1 million as of March 2025.

As of Jun 18, ENDRA Life Sciences, Inc. has a market capitalization of 2.45 million and reported net sales of 0.00 million with a net profit of -9.77 million for the latest four quarters. The company's shareholder's funds were 2.56 million, and total assets were 4.45 million as of December 2024.